Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00442
|
|||||
| Drug Name |
Rocuronium
|
|||||
| Synonyms |
(2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane; Esmeron (TN); Zemuron (TN); [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Muscle relaxant [ICD11: XM31L2] | Approved | [1] | |||
| Therapeutic Class |
Neuromuscular Nondepolarizing Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C32H53N2O4+
|
|||||
| Canonical SMILES |
CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C
|
|||||
| InChI |
InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1
|
|||||
| InChIKey |
YXRDKMPIGHSVRX-OOJCLDBCSA-N
|
|||||
| CAS Number |
CAS 119302-91-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 529.8 | Topological Polar Surface Area | 59 | ||
| Heavy Atom Count | 38 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10298784
, 104625114
, 123090170
, 134337660
, 136177198
, 137004290
, 152258743
, 160647588
, 160964072
, 162177643
, 162201757
, 163306169
, 163414334
, 175266560
, 175443879
, 176484263
, 176484981
, 178100829
, 179149670
, 184811987
, 223383273
, 224380718
, 226416911
, 241035612
, 251916699
, 251917938
, 252356492
, 36885162
, 46506855
, 50112687
, 57403615
, 76758492
, 7980535
, 87322634
, 92309079
, 92729760
, 93166518
, 9759
|
|||||
| ChEBI ID |
CHEBI:8884
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [2] | |
| OATP2B1 | Transporter Info | Organic anion transporting polypeptide 2B1 | Substrate | [3] | ||
| References | ||||||
| 1 | Rocuronium was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther. 1999 Oct;291(1):147-52. | |||||
| 3 | Drug Interactions in Infectious Diseases. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.